Theranica Reaches Migraine PDT Agreement with Massachusetts Medicare

Members who receive healthcare through Point43Health Inc.’s programs will now be able to access a device called Nerivio.

The makers of a digital prescription therapy designed to treat migraines and pain have reached an agreement to launch a year-long pilot program with a Massachusetts-based health insurer.

Theranica Bio-Electronics, Ltd., a company focused on using digital tools to treat neurological pain, last month announced an agreement with Point32Health, Inc., the parent company of Harvard Pilgrim Health Care and Tufts Health. Plan.

Under the terms of the agreement, Points32Health will make Theranica’s Nerivio therapeutic treatment available to its commercial insurance members for 12 months. Nerivio is a wearable device that fits on a patient’s upper arm and is controlled by a smartphone app. It is intended to treat chronic and episodic migraines in people 12 years of age and older.

Michael Sherman, MD, MBA, MS, executive vice president and chief medical officer of Point32Health, noted that migraines affect approximately 10% of the population.

“We are delighted to be working with Theranica to offer Nerivio as a drug-free solution for our members suffering from acute migraines and recurrent attacks,” he said in a press release. “This pilot project underscores our commitment to providing access to a wide range of medical devices and tools that support healthy living.

Nerivio has been cleared by the FDA as a migraine treatment and is available by prescription. The therapy is drug-free. Instead of drugs, the device uses remote electrical neuromodulation to stimulate an endogenous analgesic mechanism in the patient. The process, known as “conditioned pain modulation,” can be initiated at the onset of a migraine in order to lessen symptoms, the company said.

Theranica is also investigating the use of therapy as a preventative tool to reduce the number of migraines a patient experiences.

Sait Ashina, MD, assistant professor of neurology at Beth Israel Deaconess Medical Center and Harvard Medical School, said the increased availability of Nerivio is important because it expands the potential treatments available to patients.

“Many of my patients have found Nerivio to be very effective for them,” Ashina said in the press release. “Given the multifaceted complexity of migraine, it is essential that patients have access to a wide range of therapies, both pharmacological and non-drug.”

Theranica said the device can be used as a stand-alone treatment or in combination with other therapies.

Once prescribed, the company delivers the cuff directly to patients’ homes. The device is good for 12 treatments, after which it can be recycled and a new device can be given out.

The agreement with Point32Health is the latest agreement Theranica has entered into to increase the availability of Nerivio. In June, the company announced that Costco would add Nerivio to its membership prescription program. Last year, the company signed an agreement with the Department of Veterans Affairs to allow veterans access to therapy.

“We are committed to making Nerivio accessible to migraine sufferers who seek cost-effective, chemical-free therapies to manage this debilitating condition,” said Alon Ironi, CEO of Theranica. “We look forward to working with Point32Health and the healthcare providers participating in this pilot, and forging additional strategic collaborations to ensure widespread access to this disruptive technology therapy.”


Add Comment